Preparedness Platform

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:44 publications

Grant number: MC_UU_00034/6

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2023
    2028
  • Known Financial Commitments (USD)

    $3,703,880
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. Emma Thomson
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Glasgow
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Emerging viruses pose a significant threat to the health and wellbeing of the UK population. Increased contact between humans and zoonotic reservoirs due to anthropogenic change means that the likelihood of outbreaks is increasing. Strategies will be required to reduce the risk of outbreaks at source and to contain them once they are established. In the Preparedness platform, we will build on infrastructure developed during our research response to the COVID-19 pandemic and on strong UK and international partnerships, aiming better to understand, prevent, detect and respond to viral threats to human health. The aims of this framework have been developed in consultation with colleagues in the UK Health Security Agency (UKHSA) at Porton (Rare and Imported Pathogens Laboratory) and Colindale, Public Health Scotland (PHS) and our international partners in Uganda and Malawi to identify key areas that require research innovation and development. Activities will be organised around three central themes that require innovative research-based approaches for enhanced surveillance and preparedness, employing emerging technologies that align with the strengths of the CVR. The platform is designed to be flexible, to integrate core funded activities and externally funded projects that benefit from access to the underpinning infrastructure that includes expertise in genomics and bioinformatics, molecular virologists, clinicians embedded within the NHS, staff with joint appointments with the UK public health agencies, a serology laboratory, an outbreak biorepository, CL3 facilities and data linkage systems. This represents an unrivalled combination of resources and expertise. We have recently demonstrated how we can rapidly pivot to address emerging viruses and aim to build on this experience.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Variable rates of SARS-CoV-2 evolution in chronic infections.

Uncovering the viral aetiology of undiagnosed acute febrile illness in Uganda using metagenomic sequencing.

Epidemiology of Human Seasonal Coronaviruses Among People With Mild and Severe Acute Respiratory Illness in Blantyre, Malawi, 2011-2017.

Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.

HPV and RNA Binding Proteins: What We Know and What Remains to Be Discovered.

Spatio-temporal spread of Lassa virus and a new rodent host in the Mano River Union area, West Africa.

Assessing the feasibility of applying machine learning to diagnosing non-effusive feline infectious peritonitis.

The airborne transmission of viruses causes tight transmission bottlenecks.

Serological and Molecular Investigation of SARS-CoV-2 in Horses and Cattle in Switzerland from 2020 to 2022.